论文部分内容阅读
阿托伐他汀钙是3-羟基-3-甲基戊二酰辅酶A(HMG-Co A)还原酶的选择性、竞争性抑制剂,通过阻断HMG-Co A而显著减少胆固醇的合成,同时具有稳定动脉硬化斑块等降脂以外的作用,2001年5月被美国脂质教育项目(NCEP)列为高胆固醇血症的首选药物[1],广泛应用于治疗高胆固醇血症、冠心病和脑动脉硬化等疾病。阿托伐他汀钙作为一种新型降脂类药物,其不良反应报告(ADR)也呈增加趋势,现将我院18例阿托伐
Atorvastatin calcium is a selective, competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-Co A) reductase that significantly reduces cholesterol synthesis by blocking HMG-Co A, At the same time has the role of stabilizing atherosclerotic plaque and other lipid-lowering addition. In May 2001, it was listed as the first choice of hypercholesterolemia by the United States Lipid Education Program (NCEP) [1], which is widely used in the treatment of hypercholesterolemia, Heart disease and cerebral arteriosclerosis and other diseases. Atorvastatin calcium as a new type of lipid-lowering drugs, the adverse reaction report (ADR) also showed an increasing trend, now in our hospital 18 cases of atorvastatin